P1: Japanese ADNI: Clinical, neuroimaging and biomarker profiles in comparison with ADNI
Takeshi Iwatsubo, MD, Atsushi Iwata, MD, Kazushi Suzuki, MD, Ryoko Ihara, MD, Hiroyuki Arai, MD, Kenji Ishii, MD, Michio Senda, MD, Kengo Ito, MD, Takeshi Ikeuchi, MD, Ryozo Kuwano, MD, Hiroshi Matsuda, MD, for the Japanese ADNI and Chung-Kai Sun, PhD, Laurel Beckett PhD, Paul Aisen, MD, Michael Donohue, PhD, for the ADNI
(1) The University of Tokyo, Tokyo, Japan (2) Tohoku University, Sendai, Japan (3) Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan (4) Institute of Biomedical Research and Innovation, Kobe, Japan (5) National Center for Geriatrics and Gerontology, Obu, Japan (6) Niigata University, Niigata, Japan (7) National Center for Neurology and Psychiatry, Kodaira, Japan (8) Alzheimer Therapeutics Research Institute, University of Southern California, San Diego, CA, USA (9) University of California, Davis, Sacramento, CA, USA

P2: Putting the PGSA to the test: Time to progression in five studies with MCI patients
Manfred Berres, PhD, RheinAhrCampus, Remagen, Germany; Andreas U. Monsch, PhD, Memory Clinic, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland and René Spiegel, PhD, University Center for Medicine of Aging, Felix Platter Hospital, Basel, Switzerland.

P3: The importance of correct specification of the within-subject correlation structure in sample size calculation and power analysis for an AD clinical trial utilizing mixed effects regression analysis for outcome assessment
Wenyaw Chan, Ph.D., Ho-Lan Peng, Ph.D., Valory N. Pavlik, Ph.D.
(1) Department of Biostatistics, University of Texas Health Science Center at Houston, Houston, Texas, USA (2) Department of Neurology, Baylor College of Medicine, Houston, Texas, USA

P4: Join Dementia Research Improving Delivery of Clinical Trials in the UK
Adam Smith, Office of the NIHR National Director for Dementia Research, University College London, UK

P5: Evaluation of Rapid, on-Site APOE Genetic Testing for Subject Outreach and Trial Recruitment
Sharon Cohen, MD FRCP, Stephen G. Thein, PhD, Ian Cohen, MD CCFP, Sophia Marie Pagtahkan, MD, Fadi Frankul, MBChB
(1) Toronto Memory Program, Toronto, ON, Canada (2) Pacific Research Network, San Diego, CA, USA

P6: Implementing a Memory Clinic Model to facilitate recruitment into early phase clinical trials for Mild Cognitive Impairment and Alzheimer’s Disease
Lovingly Park, MD, Lev Gertsik, M.D., Zyanya Mendoza, PsyD, Katrina Patrick, Ph.D., Darlene Gullaba, Airybelle Rodriguez, and Stanford Jhee, PharmD
(1) PAREXEL International, Glendale, CA (2) California Clinical Trials Medical Group, Glendale, CA, USA

P7: AD clinical trial recruitment Capacity to screen delivers faster recruitment
Roger Bullock, MD, Mette G. Skaksen, Susanne B. Olesen, Aina S. Lihn, MD, PhD
Ulla Schmidt, MD, Hans Chr. Hoock MD, PhD
(1) Bioclinica Research Network, Stans NW, Switzerland; (2) Bioclinica Research Network, Aalborg, Denmark; (3) Bioclinica Research Network, Vejle, Denmark; (4) Bioclinica Research Network, Ballerup, Denmark
P8: Clinical and psychometric characteristics of participants with preclinical Alzheimer’s disease in Japanese ADNI
Ryoko Ihara, MD, Atsushi Iwata, MD, Kazushi Suzuki, MD, Takeshi Iwatsubo, MD, Hiroyuki Arai, MD, Kenji Ishii, MD, Michio Senda, MD, Kengo Ito, MD, Takeshi Ikeuchi, MD, Ryozo Kuwano, MD, Hiroshi Matsuda, MD, for the Japanese ADNI

P9: A novel mixed effects model to simultaneously estimate how the baseline value and the longitudinal change in biomarkers predict the change in cognition in dominantly inherited Alzheimer’s disease
Guoqiao Wang, PhD, Chengjie Xiong, PhD, Eric M. McDade, DO, Jason Hassenstab, PhD, Anne M. Fagan, PhD, Tammie L.S. Benzinger, PhD, John C. Morris, MD, Andrew J. Aschenbrenner, PhD, Randall J. Bateman, MD
The Dominantly Inherited Alzheimer Network, Department of Neurology, Washington University School of Medicine, St. Louis, MO

P10: An examination of rate of decline as an alternative to change from baseline
Howard Mackey, PhD, Nan Hu, PhD, Michael Malek-Ahmedi, MS, Yinhua Chen, MSC, Pierre Tariot, MD, Eric M Reiman, MD, Francisco Lopera, MD, Kewei Chen, PhD, Ronald Thomas, PhD
(1) Genentech, Inc., South San Francisco, CA, USA (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA
(3) Universidad de Antioquia, Medellin, Colombia (4) UC San Diego Department of Neurosciences, CA, USA

P11: Metric Collection for Research Site Optimization: Global Alzheimer’s platform efforts toward creating an AD research site database.
Richard Mohs, PhD, Kate Zhong, MD, John Dwyer, JD, Jason Bork, MA, Gabe Goldfeder, MA
Global Alzheimer’s Platform, Washington, D.C., USA

P12: In vitro degradation of β-amyloid fibrils by microbial keratinases
Debananda Singh Ningthoujam,
DBT-State Biotech Hub (SBT Hub) & Microbial Biotechnology Research Laboratory (MBRL), Department of Biochemistry, Manipur University, Canchipur, Imphal

P13: A likelihood-based prediction of Alzheimer’s dementia using biomarkers: applications for clinical trials
Igor Yakushev, MD, Felix Müller-Sarnowski, MD, Bing Si, PhD, Jing Li, PhD, Timo Grimmer, MD
(1) Dept. of Nuclear Medicine, Technical University of Munich (2) Dept. of Psychiatry and Psychotherapy, Technical University of Munich (3) Dept. of Industrial Engineering, Arizona State University

P14: A randomized placebo-controlled cross-over trial investigating nabilone as a treatment for agitation in patients with advanced AD: study protocol
Myuri Ruthirakuan, PhD(c), Nathan Herrmann, MD, FRCP(c), Eileen H. Abraham, BSc, Chelsea Sherman, BSc, Nicolaas Paul L.G. Verhoeff, MD, FRCP(c), PhD, Alex Kiss, PhD, Sandra E. Black, MD, FRCP(c), Ana C. Andreazza, Ph.D and Krista L. Lancot, PhD
(1) Sunnybrook Research Institute, Toronto, ON, Canada (2) University of Toronto, Toronto, ON, Canada (3) Neuropsychopharmacology Research Group, Toronto, ON, Canada (4) Baycrest Health Sciences, Toronto, ON, Canada

P15: Enriching Clinical Trial Data through Co-enrollment with the Brain Health Registry
P16: Outcomes and Length of Pharmacotherapy Trials on Alzheimer’s disease
Enea Traini, PhD¹, Michele Moruzzi, PhD², Francesco Amenta, MD¹
Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino

P17: Electrophysiology of the GABA and Cholinergic systems in healthy elderly subjects
Kristinn Johnsen, PhD¹, Peter Draxler, PhD¹, Gísli Johannesson, PhD¹, Magnus Johannsson, MSc¹, Thorkell Gudmundsson, MD², Jon Snaedal, MD²
(1) Research and Development, MentisCura, Reykjavík, Iceland. (2) Geriatrics, Landspitali University Hospital, Reykjavík, Iceland.

Christopher Weber, PhD¹, Selam Negash, PhD¹, Michael Ropacki, PhD¹, Christopher Randolph, PhD¹,²
(1) MedAvante, Inc. (2) Loyola University Medical Center

P19: Study design and protocol of the Nolan trial: A randomized controlled trial of a nutritional blend to prevent cognitive decline in older adults
Claudie Hooper, PhD¹, Sophie Guyonnet, PhD¹,², Corina Boschat PhD³, Julie Hudry PhD³, Sandrine Andrieu MD, PhD²,⁴, Jeronen Schmitt PhD³,⁵, Bruno Vellas MD, PhD¹.
(1) Gérontopôle, Department of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France. (2) UMR1027, Université de Toulouse, UPS, INSERM, Toulouse, France. (3) Nestlé Research Center, Vers-chez-les-Blanc, Switzerland. (4) Department of Epidemiology and Public Health, CHU Toulouse, Toulouse, France. (5) Center of Human Psychopharmacology, Swinburne University of Technology, Melbourne, Australia.

P20: Validating Trial Power in Presence of Non-Random Dropouts Using Disease Simulation
Ali Tafazzoli, PhD¹, Peter L. Quon, MPH¹, Sean Stern, MS¹, Anuraag Kansal, PhD¹
(1) Evidera, Bethesda, MD, USA

P21: Accounting for baseline prognostic variables and patient drop-out in the analysis of longitudinal outcomes within randomized trials for Alzheimer’s Disease.
Elizabeth Colantuoni, PhD¹, Michael Rosenblum, PhD¹, Jon Steingrimsson, PhD¹, Aidan McDermott, PhD¹, Arnold Bakker, PhD², Michela Gallagher, PhD³,⁴
(1) Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA (2) Department of Psychiatry and Behavioral Sciences, Johns Hopkins Medical School, Baltimore, MD USA (3) AgeneBio, Inc. Baltimore, MD USA (4) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD USA
P22: An open-source implementation of data standards for Alzheimer’s Disease clinical trials
Chung-Kai Sun, MS1, Michael Donohue, PhD1, Karin Ernstrom, MS1, Yanxin Jiang, MS1, Zeyun, Lu, MS1, Paul Aisen, MD1, Rema Raman PhD1
(1) Alzheimer Therapeutics Research Institute, University of Southern California, San Diego, CA, USA

P23. Longitudinal Impact of Audio Review on Data Quality
Todd M. Solomon, PhD1,2, Jordan M. Barbone, BS1, Sarah M. Karas PsyD1, H. Todd Feaster PsyD1
(1) Bracket, Wayne, PA, USA, (2) Boston University School of Medicine, Boston, MA, USA

P24. Utilizing Audio Review to Improve ADCS-ADL Data Quality
Todd M. Solomon1,2 PhD, H. Todd Feaster PsyD1, Jordan M. Barbone, BS1 and David S. Miller, MD, MA1
(1) Bracket, Wayne, PA, USA; (2) Boston University School of Medicine, Boston, MA, USA

P25: The influence of a mobility training program on gait performance among healthy cognitive elderly people and people with MCI
Carine Federspiel, MD1,2, Elisabeth Bourkel, PhD1, Jean-Paul Steinmetz, PhD1,2
(1) Centre for memory and mobility, Luxembourg; (2) ZithaSenior, Research & Development, Luxembourg